Brant, Emily B. http://orcid.org/0000-0002-0207-8210
Kennedy, Jason N.
King, Andrew J. http://orcid.org/0000-0002-9809-0563
Gerstley, Lawrence D.
Mishra, Pranita
Schlessinger, David
Shalaby, James
Escobar, Gabriel J. http://orcid.org/0000-0003-2540-3327
Angus, Derek C.
Seymour, Christopher W.
Liu, Vincent X.
Funding for this research was provided by:
Gordon and Betty Moore Foundation (8857, 8857, 8857)
U.S. Department of Health & Human Services | National Institutes of Health (2-T32-HL007820-21, R35GM119519, K23GM104022, R35GM128672)
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
Article History
Received: 16 September 2021
Accepted: 24 February 2022
First Online: 4 April 2022
Competing interests
: Dr. Angus reports receiving personal fees from and serving as a consultant to Ferring Pharmaceuticals, Bristol-Myers Squibb, Bayer AG, and Beckman Coulter Inc; owning stock in Alung Technologies; and having patent applications pending for selepressin (compounds, compositions, and methods for treating sepsis) and proteomic biomarkers of sepsis in elderly patients. Dr. Seymour reports receiving personal fees from Edwards Inc. and Beckman Coulter Inc. No other conflicts of interest were reported.